Martina Gropp‐Meier

3.0k total citations
17 papers, 130 citations indexed

About

Martina Gropp‐Meier is a scholar working on Reproductive Medicine, Oncology and Immunology. According to data from OpenAlex, Martina Gropp‐Meier has authored 17 papers receiving a total of 130 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Reproductive Medicine, 12 papers in Oncology and 4 papers in Immunology. Recurrent topics in Martina Gropp‐Meier's work include Ovarian cancer diagnosis and treatment (14 papers), PARP inhibition in cancer therapy (9 papers) and BRCA gene mutations in cancer (3 papers). Martina Gropp‐Meier is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), PARP inhibition in cancer therapy (9 papers) and BRCA gene mutations in cancer (3 papers). Martina Gropp‐Meier collaborates with scholars based in Germany, France and Italy. Martina Gropp‐Meier's co-authors include Günther Wiedemann, Philipp Harter, Gerhard W. Fischer, Andreas du Bois, Philipp Bücke, Christian Peschel, Christine M Pfeiffer, Katharina S. Götze, Thomas Decker and Jalid Sehouli and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Gynecologic Oncology.

In The Last Decade

Martina Gropp‐Meier

15 papers receiving 129 citations

Peers

Martina Gropp‐Meier

ONCOL

IMMUN

Santhosh Sivajothi United States

P. Hoskins Canada

T. Cameron United States

Vasudha Sehgal United States

M.P. Barretina Ginesta Spain

Yoko Kayukawa United States

Alexandra Tyulyandina Russia

Ginés Hernández-Cortes Spain

Ming-Mo Hou Taiwan

Eugenia Ortega Spain

Santhosh Sivajothi United States

Martina Gropp‐Meier

25 ×0.3

ONCOL

75 ×1.0

91 ×3.0

IMMUN

25 ×1.2

62 ×3.1

Citations per year, relative to Martina Gropp‐Meier Martina Gropp‐Meier (= 1×) peers Santhosh Sivajothi

Countries citing papers authored by Martina Gropp‐Meier

Since Specialization

Citations

This map shows the geographic impact of Martina Gropp‐Meier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martina Gropp‐Meier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martina Gropp‐Meier more than expected).

Fields of papers citing papers by Martina Gropp‐Meier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martina Gropp‐Meier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martina Gropp‐Meier. The network helps show where Martina Gropp‐Meier may publish in the future.

Co-authorship network of co-authors of Martina Gropp‐Meier

This figure shows the co-authorship network connecting the top 25 collaborators of Martina Gropp‐Meier. A scholar is included among the top collaborators of Martina Gropp‐Meier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martina Gropp‐Meier. Martina Gropp‐Meier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Gebski, Val, Florence Joly, Jonathan A. Ledermann, et al.. (2024). Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Gynecologic Oncology. 192. 50–55.

Cloven, Noelle, Henrik Roed, Lucy Gilbert, et al.. (2024). PO001/#1130 Impact of investigator-assessed response to dostarlimab on quality of life in the ruby trial of primary advanced or recurrent endometrial cancer (PA/REC). A14–A15. 1 indexed citations

Heitz, Florian, Christian Marth, Stéphanie Henry, et al.. (2023). AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. International Journal of Gynecological Cancer. 33(12). 1966–1969. 11 indexed citations

Ray-Coquard, Isabelle Laure, Alexandra Léary, Sandro Pignata, et al.. (2022). LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). Annals of Oncology. 33. S1396–S1397. 29 indexed citations

Hietanen, Sakari, Patricia Pautier, Philipp Harter, et al.. (2021). RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma. Gynecologic Oncology. 162. S71–S71. 1 indexed citations

Canzler, Ulrich, Hans‐Joachim Lück, Petra Neuser, et al.. (2020). Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. Archives of Gynecology and Obstetrics. 301(5). 1267–1274. 6 indexed citations

Hasenburg, Annette, Jalid Sehouli, Bjoern Lampe, et al.. (2020). LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. International Journal of Gynecological Cancer. 30(10). 1548–1553. 5 indexed citations

Schnelzer, Andreas, Philipp Harter, Jalid Sehouli, et al.. (2020). Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Geburtshilfe und Frauenheilkunde. 3 indexed citations

Harter, Philipp, Jalid Sehouli, Werner Meier, et al.. (2020). Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20. Geburtshilfe und Frauenheilkunde. 7 indexed citations

10.

Heitz, Florian, et al.. (2018). Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und Frauenheilkunde. 1 indexed citations

11.

Hasenburg, Annette, Jalid Sehouli, Alexander Reuß, et al.. (2018). LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study.. Journal of Clinical Oncology. 36(15_suppl). 5575–5575. 4 indexed citations

12.

Harter, Philipp, Jalid Sehouli, Werner Meier, et al.. (2018). Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO DESKTOP III/ENGOT ov20. Geburtshilfe und Frauenheilkunde.

13.

Penson, Richard T., JA Ledermann, Christopher Brown, et al.. (2017). Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology. 28. v331–v331. 4 indexed citations

14.

Harter, Philipp, Jalid Sehouli, Alexander Reuß, et al.. (2016). Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7). International Journal of Gynecological Cancer. 26(9). 1636–1641. 5 indexed citations

15.

Kurzeder, Christian, José María Del Campo, Patricia Pautier, et al.. (2014). PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS5613–TPS5613. 3 indexed citations

16.

Meier, Werner, Andreas du Bois, Jörn Rau, et al.. (2012). Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB–IV. Gynecologic Oncology. 126(2). 236–240. 19 indexed citations

17.

Decker, Thomas, Gerhard W. Fischer, Philipp Bücke, et al.. (2012). Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. Journal of Cancer Research and Clinical Oncology. 138(11). 1945–1950. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact